HK1212339A1 - Substituted pyridine derivatives useful as c-fms kinase inhibitors c-fms - Google Patents
Substituted pyridine derivatives useful as c-fms kinase inhibitors c-fmsInfo
- Publication number
- HK1212339A1 HK1212339A1 HK16100226.8A HK16100226A HK1212339A1 HK 1212339 A1 HK1212339 A1 HK 1212339A1 HK 16100226 A HK16100226 A HK 16100226A HK 1212339 A1 HK1212339 A1 HK 1212339A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- fms
- kinase inhibitors
- pyridine derivatives
- substituted pyridine
- derivatives useful
- Prior art date
Links
- 108010058398 Macrophage Colony-Stimulating Factor Receptor Proteins 0.000 title 2
- 229940043355 kinase inhibitor Drugs 0.000 title 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 title 1
- 150000003222 pyridines Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- AIDS & HIV (AREA)
- Ophthalmology & Optometry (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Molecular Biology (AREA)
- Reproductive Health (AREA)
- Cardiology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361791007P | 2013-03-15 | 2013-03-15 | |
| PCT/US2014/025308 WO2014151258A1 (en) | 2013-03-15 | 2014-03-13 | Substituted pyridine derivatives useful as c-fms kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1212339A1 true HK1212339A1 (en) | 2016-06-10 |
Family
ID=50897867
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK16100226.8A HK1212339A1 (en) | 2013-03-15 | 2016-01-11 | Substituted pyridine derivatives useful as c-fms kinase inhibitors c-fms |
| HK18110479.9A HK1250986A1 (zh) | 2013-03-15 | 2018-08-15 | 可用作c-fms激酶抑制劑的取代的吡啶衍生物 |
| HK19101388.7A HK1258911A1 (zh) | 2013-03-15 | 2019-01-28 | 可用作c-fms激酶抑制劑的取代的吡啶衍生物 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK18110479.9A HK1250986A1 (zh) | 2013-03-15 | 2018-08-15 | 可用作c-fms激酶抑制劑的取代的吡啶衍生物 |
| HK19101388.7A HK1258911A1 (zh) | 2013-03-15 | 2019-01-28 | 可用作c-fms激酶抑制劑的取代的吡啶衍生物 |
Country Status (19)
| Country | Link |
|---|---|
| US (4) | US9611259B2 (xx) |
| EP (2) | EP3284742A1 (xx) |
| JP (1) | JP6384022B2 (xx) |
| CN (2) | CN105026388B (xx) |
| AU (1) | AU2014235183B9 (xx) |
| CY (1) | CY1120185T1 (xx) |
| DK (1) | DK2970232T3 (xx) |
| ES (1) | ES2662600T3 (xx) |
| HK (3) | HK1212339A1 (xx) |
| HR (1) | HRP20180632T1 (xx) |
| HU (1) | HUE036925T2 (xx) |
| LT (1) | LT2970232T (xx) |
| MX (1) | MX365315B (xx) |
| NO (1) | NO3090256T3 (xx) |
| PL (1) | PL2970232T3 (xx) |
| PT (1) | PT2970232T (xx) |
| RS (1) | RS57103B1 (xx) |
| SI (1) | SI2970232T1 (xx) |
| WO (1) | WO2014151258A1 (xx) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2014235183B9 (en) | 2013-03-15 | 2018-04-05 | Janssen Pharmaceutica Nv | Substituted pyridine derivatives useful as c-fms kinase inhibitors |
| TWI752980B (zh) * | 2016-07-18 | 2022-01-21 | 比利時商健生藥品公司 | 4-氰基-n-(2-(4,4-二甲基環己-1-烯-1-基)-6-(2,2,6,6-四甲基四氫-2h-哌喃-4-基)吡啶-3-基)-1h-咪唑-2-甲醯胺之晶型 |
| TW201811326A (zh) * | 2016-07-18 | 2018-04-01 | 比利時商健生藥品公司 | ４－氰基－ｎ－（２－（４，４－二甲基環己－１－烯－１－基）－６－（２，２，６，６－四甲基四氫－２ｈ－哌喃－４－基）吡啶－３－基）－１ｈ－咪唑－２－甲醯胺之鹽形式 |
| JP2020510673A (ja) * | 2017-03-03 | 2020-04-09 | ヤンセン バイオテツク，インコーポレーテツド | がんの治療のための低分子ｃｓｆ−１ｒ阻害剤とｃｄ４０に特異的に結合するアゴニスト抗体とを含む併用療法 |
| WO2018182527A1 (en) * | 2017-03-30 | 2018-10-04 | National University Of Singapore | Method for treating inflammatory complications in eye diseases |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5521184A (en) | 1992-04-03 | 1996-05-28 | Ciba-Geigy Corporation | Pyrimidine derivatives and processes for the preparation thereof |
| US7135575B2 (en) * | 2003-03-03 | 2006-11-14 | Array Biopharma, Inc. | P38 inhibitors and methods of use thereof |
| PL1807077T3 (pl) * | 2004-10-22 | 2017-05-31 | Janssen Pharmaceutica Nv | Inhibitory kinazy c-fms |
| JO3240B1 (ar) * | 2007-10-17 | 2018-03-08 | Janssen Pharmaceutica Nv | c-fms مثبطات كيناز |
| WO2009058968A2 (en) * | 2007-10-31 | 2009-05-07 | Janssen Pharmaceutica N.V. | Biomarker for assessing response to fms treatment |
| AU2014235183B9 (en) | 2013-03-15 | 2018-04-05 | Janssen Pharmaceutica Nv | Substituted pyridine derivatives useful as c-fms kinase inhibitors |
-
2014
- 2014-03-13 AU AU2014235183A patent/AU2014235183B9/en not_active Ceased
- 2014-03-13 SI SI201430613T patent/SI2970232T1/en unknown
- 2014-03-13 EP EP17190920.3A patent/EP3284742A1/en not_active Withdrawn
- 2014-03-13 MX MX2015012343A patent/MX365315B/es active IP Right Grant
- 2014-03-13 RS RS20180441A patent/RS57103B1/sr unknown
- 2014-03-13 LT LTEP14729096.9T patent/LT2970232T/lt unknown
- 2014-03-13 ES ES14729096.9T patent/ES2662600T3/es active Active
- 2014-03-13 DK DK14729096.9T patent/DK2970232T3/en active
- 2014-03-13 HU HUE14729096A patent/HUE036925T2/hu unknown
- 2014-03-13 EP EP14729096.9A patent/EP2970232B1/en active Active
- 2014-03-13 JP JP2016501816A patent/JP6384022B2/ja active Active
- 2014-03-13 WO PCT/US2014/025308 patent/WO2014151258A1/en active Application Filing
- 2014-03-13 PT PT147290969T patent/PT2970232T/pt unknown
- 2014-03-13 CN CN201480015688.9A patent/CN105026388B/zh active Active
- 2014-03-13 US US14/772,040 patent/US9611259B2/en active Active
- 2014-03-13 CN CN201810396318.4A patent/CN108341805A/zh active Pending
- 2014-03-13 PL PL14729096T patent/PL2970232T3/pl unknown
- 2014-12-02 NO NO14824967A patent/NO3090256T3/no unknown
-
2016
- 2016-01-11 HK HK16100226.8A patent/HK1212339A1/xx not_active IP Right Cessation
-
2017
- 2017-02-23 US US15/440,182 patent/US10071991B2/en active Active
-
2018
- 2018-04-20 HR HRP20180632TT patent/HRP20180632T1/hr unknown
- 2018-04-27 CY CY20181100448T patent/CY1120185T1/el unknown
- 2018-08-13 US US16/102,005 patent/US10800764B2/en active Active
- 2018-08-15 HK HK18110479.9A patent/HK1250986A1/zh unknown
-
2019
- 2019-01-28 HK HK19101388.7A patent/HK1258911A1/zh unknown
-
2020
- 2020-09-02 US US17/010,132 patent/US11214566B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1221466A1 (zh) | 作為 抑制劑的聯吡唑衍生物 | |
| HRP20170940T1 (hr) | Derivati piridina kao lako razgradivi rock inhibitori | |
| ZA201603337B (en) | Pyrimidopyrimidinones useful as wee-1 kinase inhibitors | |
| SG11201600062RA (en) | Pyrimidine derivatives as kinase inhibitors | |
| IL245660B (en) | History of aminopyridines as tam family kinase inhibitors | |
| EP2981535B8 (en) | Urea derivatives useful as kinase inhibitors | |
| HK1211578A1 (en) | Amidoimidazopyridazines as mknk-1 kinase inhibitors mknk-1 | |
| IL245443A0 (en) | Disubstituted pyridine derivatives are useful as gsk–3 inhibitors | |
| HK1258911A1 (zh) | 可用作c-fms激酶抑制劑的取代的吡啶衍生物 | |
| IL274874A (en) | Dialkyl(oxido)-4 LAMDA-converted sulfenylidine nicotinamide derivatives as kinase inhibitors | |
| EP2968324A4 (en) | SUBSTITUTED PYRIDONE DERIVATIVES AS PDE10 INHIBITORS | |
| HK1217654A1 (zh) | 作爲激酶抑制劑的呋喃酮化合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20240313 |